FDA MedWatch Safety AlertsOriginal article
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
RegulatoryrejectedTyenneNegative
AI Analysis
Summary
Fresenius Kabi issued a nationwide recall of one lot of Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL vials due to the presence of glass particles detected during internal investigation. The recall extends to the user level.
Outcome Details
Product recall issued due to presence of glass particles in Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL vials. One lot recalled to user level.
Importance:7/10
Sentiment:
-0.90
product recallsafety issueglass particlesinjectableFDA MedWatch
Read the original article
Published by FDA MedWatch Safety Alerts on August 11, 2026 4:00 AM